
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
This AJMC® Clinical Brief provides highlights from an analysis of NHANES data that was performed to determine the prevalence and degree of overlap of cardiac, renal, and metabolic conditions among US adults.






